Company intelligence / Profile preview

ZielBio

Charlottesville, Virginia, United Statesorpha.net ↗

Ownership: Private
Development stage: Other

Overview

ZielBio’s lead asset ZB131—a proprietary monoclonal antibody targeting CSP—has received FDA Orphan Drug Designation for both pancreatic cancer and cholangiocarcinoma. A Phase 1/2 clinical trial of ZB131 in advanced solid tumors including pancreatic cancer is actively enrolling patients as of late 2022. The company leverages its Zielfind™ technology to identify new druggable targets with a focus on oncology.[4][5][6]

Therapeutic areas: OtherOncology
Modalities: monoclonal antibodies (mAbs)therapeutic interventions (general)
Industry: Biotech

Drug pipeline

3 assets

ibentatug

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ZielBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZielBio.

Explore the full profile